Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
Sportschosun on MSN1d
A drop of blood distinguishes Crohn's disease from ulcerative colitis...Laying the foundation for customized treatment of inflammatory bowel diseaseInflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team ...
Ulcerative colitis (UC) is a chronic inflammatory disease of the gastrointestinal tract, characterized by inflammation and ...
Colorectal cancer is preventable. Screening is the best way to improve chances of survival through early detection.
CRANBURY, NJ, USA I March 28, 2025 I Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
News-Medical.Net on MSN12h
Machine learning identifies key comorbidities predicting premature death in IBD patientsResearchers use machine learning models to investigate patterns between multimorbidity and premature deaths among decedents ...
Vanguard Health Care ETF (VHT) is rated a hold due to high valuations and low profitability of top holdings despite strong ...
Learn more about whether Alvotech or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Learn more about whether Alvotech or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback